ImmunoCellular Therapeutics (OTCBB:IMUC) said Friday it has elected Dr. Richard Chin to its board of directors, and has appointed him chairman of the company's compensation committee.
He has also been appointed a member of the company's audit committee.
Chin currently serves on the adjunct faculty of the San Francisco
School of Medicine for the University of California, as well as on the
board of directors of Genmedica Therapeutics, Balance Therapeutics, and
From 2008 to 2011, he served as CEO of OneWorld Health, a nonprofit
pharmaceutical company that was largely funded by the Bill and Melinda
Gates Foundation. Before that, he served as president and CEO of OXiGENE. He has also held various leadership roles with Elan Corp and Genentech Inc.
"We are pleased to welcome Dr. Chin to our Board of Directors," said
Dr. John Yu, ImmunoCellular chairman. "His extensive experience in drug
development will be valuable as the company advances its Phase II
clinical trial of ICT-107."
Earlier this week, ImmunoCellular said that its proprietary method
for manufacturing ICT-107, its dendritic cell (DC)-based vaccine for an
aggressive type of brain cancer, has shown better performance compared
to other methods for producing DC-based immunotherapies.
The company said its method has proven "meaningfully enhanced
efficiency, consistency and convenience". Analysis of manufacturing
data showed that its process can produce up to 30 vials of ICT-107
product, and 30 vials of placebo in a single production run.
Developed in collaboration with the company’s partners,
ImmunoCellular's manufacturing method uses a closed-bag system designed
to produce highly potent dendritic cells from white blood cells (WBCs)
collected from patients, and to preserve the cells for future vaccine
The process has also been optimized to produce high levels of certain
cytokines that play a key role in initiating an immune response,
Further, the final manufacturing process is not expected to require
"significant changes" prior to eventual commercialization,
ICT-107 is ImmunoCellular's lead dendritic cell-based cancer vaccine
candidate for the treatment of glioblastoma multiforme (GBM), an
aggressive type of brain cancer.
The vaccine, which is currently in phase two trials, works by
activating a patient's immune system against specific tumour associated
antigens for glioblastoma multiforme.
This is done by removing dendritic cells from a patient, loading them
with the tumour-related antigens, and re-injecting them back into the
patient's body to trigger an immune response against cancer cells
exhibiting these antigens.
In the natural human immune system, dendritic cells are responsible
for capturing, processing and presenting antigens to T-cells in the
immune system, which in turn target the antigens and destroy them.
These cells' conversion from antigen-capturing to antigen-presenting
mode, known as maturation, relies on the production of special messenger
cells known as cytokines.
Progression-free and overall survival times for GBM patients treated
with ICT-107 during the company's phase one trial of the drug continue
to be substantially longer than those associated with standard of care
(SOC) alone, the company said.
In September 2011, ImmunoCellular reported its three-year data, which
indicated an overall survival of 55 percent, compared to 16 percent
based on historical SOC.
Of the 16 newly diagnosed patients who received ICT-107, 38 percent
continue to show no tumor recurrence after three years, compared to the
historic disease-free survival rate of 6 percent with SOC.
Out of these patients, 19 percent remain disease-free after more than four years.
is a Los Angeles-based clinical-stage company that is developing
immune-based therapies for the treatment of brain and other cancers.